Braintact Ltd.
This article was originally published in Start Up
Executive Summary
Following a serious blow to the head, the initial damage to the brain may seem limited, but it's what happens afterwards that determines a victim's fate. Tragically, a few hours or even days later, the trauma may prove to have caused permanent or fatal damage. The amino acid neurotransmitter glutamate (Glu) plays a major role in the delayed but catastrophic reaction. Various pharmaceutical approaches to halting Glu-precipitated damage have thus far failed. Braintact proposes an entirely new way to treat TBI, stroke and even chronic brain diseases such as brain tumors. It seeks to lower the Glu levels in plasma without, however, touching the Glu release or receptor processes in the brain.
You may also be interested in...
Start-Up Previews (02/2008)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Scaffolds in Tissue Engineering," features profiles of BioCeramic Therapeutics, Histogen, Humacyte and Tissue Regenix. Plus these Start-Ups Across Health Care: Braintact, CleveX, Coherex Medical and Lytix Biopharma.
Start-Up Previews (02/2008)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Scaffolds in Tissue Engineering," features profiles of BioCeramic Therapeutics, Histogen, Humacyte and Tissue Regenix. Plus these Start-Ups Across Health Care: Braintact, CleveX, Coherex Medical and Lytix Biopharma.
Intelect Medical Inc.
Intelect Medical brings together a patent portfolio from the Cleveland Clinic and Cornell's Weill Medical College, and a management team experienced in neuromodulation, to usher in a new generation of deep brain stimulation. The start-up's initial target markets are traumatic brain injury and stroke.